Shares of Taysha Gene Therapies, Inc. (TSHA) are soaring 5.47% in pre-market trading on Friday, buoyed by positive analyst ratings. The gene therapy company has caught the attention of Wall Street, with multiple firms reiterating their bullish stance on the stock.
Citizens JMP analyst Silvan Tuerkcan maintained a Buy rating on Taysha Gene Therapies, setting a price target of $5.00. This vote of confidence from a respected analyst likely contributed to the positive sentiment surrounding the stock. Additionally, Canaccord Genuity also maintained its Buy rating on TSHA, further reinforcing the optimistic outlook for the company.
These favorable analyst actions suggest that Wall Street sees potential in Taysha Gene Therapies' pipeline and business prospects. As investors often look to analyst ratings for guidance, these maintained Buy ratings could be driving increased interest in TSHA shares, leading to the significant pre-market surge. However, investors should always conduct their own research and consider their risk tolerance before making investment decisions based on analyst recommendations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.